Europe Bronchodilators Market Insights Forecasts to 2033

• The Europe Bronchodilators Market Size was valued at USD 5.55 Billion in 2023.
• The Market Size is Growing at a CAGR of 3.02% from 2023 to 2033
• The Europe Bronchodilators Market Size is Expected to Reach USD 7.47 Billion by 2033

The Europe Bronchodilators Market Size is Anticipated to Reach USD 7.47 Billion by 2033, Growing at a CAGR of 3.02% from 2023 to 2033

Market Overview

Bronchodilators are medications that help improve breathing by relaxing the muscles in the lungs and widening the airways. They are commonly used to treat breathing disorders such as asthma and chronic obstructive pulmonary disease (COPD). Respiratory diseases cause nearly 1 million deaths annually and result in 10 million lost disability-adjusted life years (DALYs). In the 28 European Union (EU) countries, 15% of deaths are due to respiratory disease, with 5.8% attributed to lung cancer, 3.5% to pneumonia, and 3.4% to COPD. The bronchodilator market is shifting towards combination therapies, which offer better relief to patients who do not respond to single-drug therapy. In addition, combination therapies are more convenient for patients as they require fewer inhalations. This trend is expected to continue in the coming years, leading to growth in the European bronchodilator market.

Report Coverage

This research report categorizes the market for the Europe bronchodilators market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe bronchodilators market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe bronchodilators market.

Driving Factors

The growing occurrence of respiratory diseases in Europe is the main macroeconomic factor propelling the bronchodilator market's growth. Additionally, the rising awareness about the advantages of early diagnosis and treatment of respiratory diseases is anticipated to drive market growth. Patients with respiratory conditions prefer bronchodilator medications over other treatments as they offer rapid relief from symptoms like shortness of breath, wheezing, and coughing. Patients favor bronchodilator medications in inhaler form because they are easy to use and provide targeted relief to the lungs. Furthermore, the increasing adoption of combination therapies is another factor expected to boost market growth.

Restraining Factors

Bronchodilators have the potential to interact with other medicines, which can affect their efficacy or increase the risk of side effects. For instance, some diuretics can interact with bronchodilators. The side effects of bronchodilators can include dry mouth, hyperactivity, nausea, and vomiting. Other potential side effects are muscle tremors, restlessness, insomnia, tachycardia, palpitations, and arrhythmias.

Market Segmentation

The Europe bronchodilators market share is classified into drug class and disease.

• The beta-adrenergic bronchodilators segment is expected to hold the largest market share through the forecast period.

The Europe bronchodilators market is segmented by drug class into beta-adrenergic bronchodilators, xanthine derivatives, and anticholinergic bronchodilators. Among these, the beta-adrenergic bronchodilators segment is expected to hold the largest market share through the forecast period. Beta-adrenergic bronchodilators are medications that relax the muscles around the airways, helping to widen the bronchial airways. These medications, known as beta-2 agonists, target the receptors on smooth muscle cells to dilate the airways. Some major products in the short-acting category include levalbuterol (Xopenex HFA), albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin HFA), and epinephrine injection. Albuterol is the most significant revenue-generating molecule in this category, and the FDA has been approving more generic versions and new launches to meet the increasing demand.

• The asthma segment is expected to dominate the Europe bronchodilators market during the forecast period.

Based on the disease, the Europe bronchodilators market is divided into asthma, chronic obstructive pulmonary disease (COPD), and others. Among these, the asthma segment is expected to dominate the Europe bronchodilators market during the forecast period. This can be attributed to the growing prevalence of asthma in the population. Bronchodilators help relieve asthma by relaxing the muscle bands that tighten around the airways, which improves breathing. They also help clear mucus from the lungs. The large market share for asthma is because of the increasing number of patients affected with asthma around Europe.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe bronchodilators market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Glenmark Pharmaceuticals
• Mylan
• AstraZeneca PLC
• Sun Pharmaceutical Industries
• Boehringer Ingelheim
• GSK PLC
• Cipla Ltd DR
• Merck & Co Inc
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2023, AstraZeneca a British-Swedish multinational pharmaceutical and biotechnology company has introduced Airsupra (albuterol/budesonide) as an as-needed treatment for reducing the risk of exacerbations in individuals with asthma who are 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler combination rescue medication that contains albuterol, a short-acting beta2-agonist, and budesonide, an anti-inflammatory inhaled corticosteroid. It was developed by AstraZeneca and Avillion.

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Europe Bronchodilators Market based on the below-mentioned segments:

Europe Bronchodilators Market, By Drug Class

• Beta-Adrenergic Bronchodilators
• Xanthine Derivatives
• Anticholinergic Bronchodilators

Europe Bronchodilators Market, By Disease

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Others